Abstract:Background HER2 potently inhibits innate immunity through cGAS–STING signalling,1 meanwhile HER2 antibody induced ADCP will also lead to macrophage mediated immune suppression. Preclinical and clinical studies suggested a coordination of engagement of innate and adaptive immunity with the combination of an anti-HER2 antibody and an immune checkpoint blockade. KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes. KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86. Here we reported the interim results from an ongoing phase Ib dose escalation and expansion study assessing the safety, tolerability and preliminary efficacy for KN026 in combination with KN046. Methods This study enrolled pts with solid tumors who failed available standard of care, HER2 aberration status confirmed locally (HER2 mutation, HER2 amplification and/or HER2 overexpression). Eligible pts received combination of KN026 and KN046 at two dose levels until disease progression, unacceptable toxicity or withdrawal of informed consent (DL1: KN026 20 mg/kg Q2W + KN046 3 mg/kg Q2W; DL2: KN026 20 mg/kg Q2W with loading on Days 1, 8 of Cycle 1 + KN046 5 mg/kg Q3W). Tumor response was evaluated Q8W per RECIST 1.1. Primary endpoint was DLT and key secondary endpoints were efficacy parameters (ORR, DOR, PFS). Results As of the Jul. 13, 2020, 21 pts were enrolled into DL1 (n = 18, 3 for dose escalation) and DL2 (n = 3) (mGC/GEJ 12 pts; mCRC 7 pts; other solid tumors 2 pts). 11 pts remained on the study treatment and 10 pts discontinued treatment due to disease progression (n=5), death (n=2) and other reasons (n=3). 15 pts had HER2-positive status (11 of 15 failed previous trastuzumab therapy), 1 pts had HER2 mutation and 5 pts had HER2 low expression (without FISH amplification). No DLTs were observed. No pts experienced LVEF decreased or other clinically meaningful cardiac AEs. Treatment-related TEAEs occurred in 13 pts, of which 1 pts experienced grade 3 or above treatment-related TEAEs. 7 pts experienced irAEs, all of which were grade 1 or 2. The most common (≥ 10%) KN026 or KN046 related TEAEs were anaemia (n=5, 23.8%), AST increased (n=4, 19.0%), rash (n=4, 19.0%), diarrhea (n=4, 19.0%), blood bilirubin increased (n=3, 14.3%) and infusion related reaction (n=3, 14.3%). The objective response rate in pts with HER2-positive tumors (n = 7 efficacy evaluable pts) was 4/7 (57.1%, 95% CI 18.4~90.1%) and disease control rate 6/7 (85.7%, 95% CI 42.1~99.6%). 3 pts with HER2 mutation or low expression achieved SD including one patient with SD for more than 24 weeks. 2 death cases only received one cycle of KN026 plus KN046 due to COVID-19 restriction before died from clinical deterioration from underlying tumors. Conclusions KN026 combined with KN046 is well tolerated and has demonstrated profound anti-tumor activity in HER2-positive solid tumors. Trial Registration NCT04040699 Ethics Approval The study was approved by Beijing Cancer Hospital Institution’s Ethics Board, approval number 2019YJZ37. Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal. Reference Shiying Wu, Qian Zhang, Fei Zhang, et al. HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. Nature Cell Biology 2019;21: 1027–1040.

The Preliminary Efficacy and Safety Data of KN046 in Patients Failed on Prior Immune Checkpoint Inhibitors Therapy.

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors

A phase 2, open-label, multicenter study to evaluate the efficacy, safety, and tolerability of KN046 in combination with chemotherapy in subjects with advanced non-small cell lung cancer.

1330P Updated Results of the Efficacy and Safety of KN046 (a Bispecific Anti-Pd-l1/ctla-4) in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Failed Prior EGFR-TKI(s)

Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study

1034P A Phase II Study of KN046 (a Bispecific Anti-Pd-l1/ctla-4) in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Failed Prior EFGR-TKIs

1022P A Phase II Study of KN046 (a Bispecific Anti-Pd-l1/ctla-4) in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Failed First Line Treatment

A Multicenter, Open-Label Phase Ib/II Study of Cadonilimab (anti PD-1 and CTLA-4 Bispecific Antibody) Monotherapy in Previously Treated Advanced Non-Small-cell Lung Cancer (AK104-202 Study).

1449P the Preliminary Data from a Single-Arm, Open-Label, Multicenter Phase II Clinical Trial: KN046 Combined with Axitinib As First-Line (1L) Treatment for NSCLC

Preliminary safety and efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with KN026 (a HER2-targeted bispecific antibody) in patients with metastatic HER2-positive breast cancer: A phase II trial

KN026 (Anti-Her2 Bispecific Antibody) in Patients with Previously Treated, Advanced HER2-expressing Gastric or Gastroesophageal Junction Cancer.

339 Preliminary Safety, Tolerability and Efficacy Results of KN026 (a HER2-targeted Bispecific Antibody) in Combination with KN046 (an Anti-Pd-l1/ctla-4 Bispecific Antibody) in Patients (pts) with HER2 Aberrated Solid Tumors

A Phase Ib Study of KN026, a Bispecific Anti-HER2 Antibody, Combined with KN046, an Anti-CTLA-4/PD-L1 Antibody, in Patients with HER2-Positive Advanced Gastrointestinal Cancer

A phase II study of KN046 monotherapy as 2 nd line and above treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

KN026, a Bispecific Anti-HER2 Antibody, Combined with KN046, an Anti-CTLA-4/PD-L1 Antibody, in Patients with HER2-positive Advanced Gastrointestinal Cancer: a multicenter, open-label, nonrandomized, phase Ib study

Efficacy and Safety of KN026 in Combination with KN046 in Patients with Locally Advanced Unresectable or Metastatic HER2-positive Other Solid Tumors

Phase I Study of KN035, a Novel Fusion Anti-PD-L1 Antibody Administered Subcutaneously in Patients with Advanced Solid Tumors in the USA.

1029P Two-year Follow-Up from KN046 in Combination with Platinum Doublet Chemotherapy As First-Line (1L) Treatment for NSCLC: an Open-Label, Multi-Center Phase II Trial

Preliminary Safety, Efficacy and Pharmacokinetics (PK) Results of KN026, a HER2 Bispecific Antibody in Patients (pts) with HER2-positive Metastatic Breast Cancer.

Abstract 1660: Preliminary Safety Tolerability & Efficacy Results of KN046 (an Anti-Pd-l1/ctla-4 Bispecific Antibody) in Combination with Nab-paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer (Mtnbc)

A phase II study evaluating KN026 monotherapy in patients (pts) with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancers (GC/GEJC).